everolimus

The drug is used for the treatment of progressive breast cancer in postmenopausal women (in combination with exemestane), unresectable or metastatic neuroendocrine tumors of the pancreas, gastrointestinal tract, or lungs, as well as for the treatment of advanced renal cell carcinoma.

Form: tablets

ATC: L01EG02

Manufacturer: Novartis Pharma Stein AG (full-cycle manufacturing)

The drug is used for the treatment of progressive breast cancer in postmenopausal women (in combination with exemestane), unresectable or metastatic neuroendocrine tumors of the pancreas, gastrointestinal tract, or lungs, as well as for the treatment of advanced renal cell carcinoma.

Form: tablets

ATC: L01EG02

Manufacturer: Novartis Pharma Stein AG (full-cycle manufacturing)

The drug is used for the treatment of progressive breast cancer in postmenopausal women (in combination with exemestane), unresectable or metastatic neuroendocrine tumors of the pancreas, gastrointestinal tract, or lungs, as well as for the treatment of advanced renal cell carcinoma.

Form: tablets

ATC: L01EG02

Manufacturer: Novartis Pharma Stein AG (full-cycle manufacturing)

The drug is used for the prevention of transplant rejection in adult patients with low to moderate immunological risk following kidney or heart transplantation. It should be used in combination with cyclosporine and corticosteroids.

Form: tablets

ATC: L04AA18

Manufacturer: Novartis Pharma Stein AG (manufacturing, quality control, primary packaging, secondary packaging, batch release)

The drug is used to treat progressive breast cancer (in postmenopausal women), neuroendocrine tumors of pancreatic, gastrointestinal, or pulmonary origin, as well as renal cell carcinoma.

Form: tablets

ATC: L01EG02

Manufacturer: PLIVA Hrvatska d.o.o.

The drug is used to treat progressive breast cancer (in postmenopausal women), neuroendocrine tumors of pancreatic, gastrointestinal, or pulmonary origin, as well as progressive renal cell carcinoma.

Form: tablets

ATC: L01EG02

Manufacturer: PLIVA Hrvatska d.o.o.

The drug is used for the treatment of progressive breast cancer in postmenopausal women (in combination with exemestane), advanced renal cell carcinoma, as well as unresectable or metastatic neuroendocrine tumors of the pancreas, gastrointestinal tract, or lungs.

Form: tablets

ATC: L01EG02

Manufacturer: Synthon Hispania, S.L. (primary, secondary packaging, quality control, batch release)

The drug is used for the treatment of progressive breast cancer in postmenopausal women (in combination with exemestane), advanced renal cell carcinoma, as well as unresectable or metastatic neuroendocrine tumors of the pancreas, gastrointestinal tract, or lungs.

Form: tablets

ATC: L01EG02

Manufacturer: Synthon Hispania, S.L. (primary, secondary packaging, quality control, batch release)

The drug is used for the treatment of progressive breast cancer in postmenopausal women (in combination with exemestane), advanced renal cell carcinoma, as well as unresectable or metastatic neuroendocrine tumors of the pancreas, gastrointestinal tract, or lungs.

Form: tablets

ATC: L01EG02

Manufacturer: Synthon Hispania, S.L. (primary, secondary packaging, quality control, batch release)

The drug is used for the treatment of progressive breast cancer in postmenopausal women (in combination with exemestane), unresectable or metastatic neuroendocrine tumors of the pancreas, gastrointestinal tract, or lungs, as well as for the treatment of advanced renal cell carcinoma.

Form: tablets

ATC: L01XE10

Manufacturer: Nacto Pharma Limited

The drug is used for the treatment of progressive breast cancer in postmenopausal women (in combination with exemestane), unresectable or metastatic neuroendocrine tumors of the pancreas, gastrointestinal tract, or lungs, as well as for the treatment of advanced renal cell carcinoma.

Form: tablets

ATC: L01XE10

Manufacturer: Nacto Pharma Limited